AN INDUSTRIAL REVOLUTION

NIIMBL (The National Institute for Innovation in Manufacturing Biopharmaceuticals) leverages a $70 million investment from the National Institute of Standards and Technology (NIST), and is designed to innovate biomanufacturing in the United States. Through partnerships among industry, academia, non-profit organizations, and federal scientists, NIIMBL will accelerate biopharmaceutical manufacturing innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry.

FOSTERING INNOVATION

Through the cooperation and collaboration of its members, NIIMBL promises to address long standing and upcoming industry challenges in the U.S. biopharmaceutical manufacturing landscape. NIIMBL will leverage federal, state, and local resources to advance the development and manufacturing of existing and emerging products including monoclonal antibodies, antibody-drug conjugates, cell immunotherapies, gene therapies, vaccines, and blood products. NIIMBL will address technology challenges as well as workforce development needs. Furthermore, NIIMBL will work to help establish relevant reference standards and materials, facilitate technology platforms to speed approval while maintaining safety and efficacy, and encouraging domestic investment in infrastructure.

NIIMBL

• A Manufacturing USA institute designed to revolutionize biopharmaceutical manufacturing
• Solves industry challenges through partnership with industry, government, academia, and non-profits
• Partners with stakeholders to train and retrain a robust, 21st century workforce

BENEFITS

• Shared risk of technology R&D and adoption through a broad investment ecosystem
• Accelerated process development
• Establishment of best practices
• Lower barrier for new technology introduction
• Sustainable processes and process development
• Access to better trained workforce
• Standardization of equipment, assays, parts, and methods
• Regulatory advancement
• Reduced cost of goods
• Supply-chain engagement, bridging gaps from researcher to supplier to manufacturer to end-user
NIIMBL: Enabling Advanced Biopharmaceutical Manufacturing

Figure 1.1
NIIMBL’s manufacturing process themes and product focus areas will significantly impact key US advanced biomanufacturing needs and enable US competitiveness through innovation, collaboration, and education.

**NEEDS**
- Domestic biomanufacturing
- Reduced medical costs
- Global competitiveness
- Secure supply of medicines/pandemic readiness
- Precision medicines
- Reduced offshoring and outsourcing
- Workforce training and education
- Standardization
- Secure supply of medicines/pandemic readiness

**OUTCOMES**
- Access to new and improved medicines
- Drug Substance
- Drug Product
- Process Control

**IMPACT**

**NATIONAL**
- Growth of globally competitive domestic industry
- Secure, integrated supply chain
- Access to new and improved medicines

**INDUSTRY**
- Flexible, adaptive manufacturing
- De-risked manufacturing innovation
- Lower costs
- Accelerated development and approval

**MEMBERSHIP INFORMATION**

Leverage the collective capabilities of NIIMBL by joining the consortium!

Please visit [NIIMBL.org](http://NIIMBL.org) to learn more.